Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 82803

Title: Targeting Epicardial Adipose Tissue: A Potential Therapeutic Strategy for Heart Failure with Preserved Ejection Fraction with Type 2 Diabetes Mellitus

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06476778
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer's Country/Territory: China
Author's Country/Territory: China

Manuscript submission date: 2022-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-01-08 17:10

Reviewer performed review: 2023-01-20 16:09

Review time: 11 Days and 22 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation
Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This review has a general and clear discussion of the definition, Anatomy, pathology, and pathophysiology of EAT, the role of EAT in diabetic HFpEF, and a series of pharmaceutic therapy targeting EAT in diabetic HFpEF. However, the authors' depth of discussion related to the interaction between EAT, HFpEF, and DM needs to be strengthened. The authors' writing of the current manuscript needs substantial improvement. Assistance from a native speaker or experienced academic writer is strongly encouraged. The importance of EAT on HFpEF with DM should be systemically toned down. The authors may read the recent literature: Diabetic HFpEF: Benko, Jakub, et al. "Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy." Journal of Diabetes Research 2022 (2022). McHugh, Kelly, et al. "Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review." Journal of the American College of Cardiology 73.5 (2019): 602-

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

611. Altara, Raffaele, et al. "Targeting obesity and diabetes to treat heart failure with preserved ejection fraction." Frontiers in endocrinology 8 (2017): 160. Abudureyimu, Miyesaier, et al. "Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics." Journal of Molecular Cell Biology (2022). Pop-Busui, Rodica, et al. "Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association." Diabetes Care 45.7 (2022): 1670-1690. EAT & Diabetic HFpEF: Elsanhoury, Ahmed, et al. "Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype." Frontiers in Cardiovascular Medicine (2021): 1031. Salvatore, Teresa, et al. "Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes." Biomolecules 12.2 (2022): 176. Iacobellis, G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 19, 593–606 (2022). https://doi.org/10.1038/s41569-022-00679-9 The comments of the current manuscript is listed as below. The line number and Page number should be added for the reviewers' conveniences. Abstract: Line 5 Page 3: What is the definition of “Diabetic HFpEF” ? Is it interchangeable with “HFpEF with DM” Does it means the etiology of HFpEF is DM, or HFpEF with the presence of DM but not necessarily the etiology. Line 11 Page 2: “improving the dysfunction of EAT” does not make sense. “Dysfunction” cannot be “improved” Also, the author repeatedly mentioned “EAT dysfunction”, which is inappropriate, as the abnormality of EAT includes both aspects of function and structure. Line 16 Page 3- This sentence is vague. What is “beneficial” for “HFpEF”: symptom relief, slowing disease progression, reducing cardiac remodeling, or improving prognosis? Line 18 Page 3- “effectiveness” is incorrect. “Efficacy” should be used The author should consider adding the statement that treating EAT should be additive to the standardized treatment of HFpEF according to the guideline. Key word:

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

2 duplicate words for EAT. Line 5 Page 4: “Effective interventions remain a severe clinical challenge due to the complex pathophysiological underpinnings.” ---This sentence does not make sense. some words like “A lack of ” should be added before “Effective intervention”--- The same mistake appears in Line 8 Page 5 Core Tips: Line 8 Page 5: “dysfunction” refers to the functional aspect, which is hard to define as “expension”. “Abnormalities”, rather than “dysfunction”, is recommended. Line 19-22 Page 5: “Although no treatment is available specifically for EAT, lifestyle management, bariatric surgery, and pharmaceutical interventions related to anti-cytokines, anti-hyperlipidemia, and anti-hyperglycemia have been shown to reduce the inflammation response or accumulation of EAT.”--- The exact text appears in the abstract, core tips, and intro. This should be edited to improve readabilities 2.1 Anatomy of EAT Line 12 Page 6: “accompanies”---This is Vague, which should mean “surround and cover”. Line 17-19 Page 6: “Microscopically, EAT consists typically of adipocytes specialized in energy storage, but also includes inflammatory cells (mainly macrophages and mast cells), immune cells, stromovascular cells, and ganglia [13].”---This is the normal histology of EAT. In a normal human being, EAT contains a small amount of inflammatory cells, but in a diseased condition, the aggregation of inflammatory cells and microvascular network expands. The pathophysiology of EAT should also be mentioned here or with 2.3 Pathophysiology of EAT. 2.2 Pathology of EAT This whole section is about the physiology of EAT, but not about the pathology of EAT. Either the subtitle or the content needs to be changed. 2.3 Pathophysiology of EAT Line 15-19 Page 7: References are needed in these two sentences. 3.1 EAT in the pathophysiology of diabetic HFPEF Line 12-15 Page 8: References are needed in these two sentences. Para 2 Page 9: The interaction between EAT and DM should be discussed here. For example, DM may accelerate EAT deposition; EAT may increase local insulin resistance. Both the pro-inflammatory effect of EAT and DM may exhibit

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

additive effects on the myocardium to worsen cardiac remodeling and coronary arteries to accelerate coronary atherosclerosis and decrease coronary blood supply, even when CAD is not the etiology of HFpEF. 3.2 Relationship between Increased EAT and Clinical Characteristics of HFpEF HFpEF not only refers to cardiac structure and mechanical function but also includes electrophysiology. Afib is common in patients with HFpEF. EAT is widely known to be closely associated with Afib (For example: Ernault, Auriane C., et al. "The Secretome of Atrial Epicardial Adipose Tissue Facilitates Reentrant Arrhythmias by Myocardial Remodeling." Heart Rhythm (2022).; Ernault, Auriane C., Veronique MF Meijborg, and Ruben Coronel. "Modulation of cardiac arrhythmogenesis by epicardial adipose tissue: JACC State-of-the-Art Review." Journal of the American College of Cardiology 78.17 (2021): 1730-1745.). This should be considered to be discussed. Additionally, any literature on histology & pathology between EAT and HF, as well as DM, is recommended to be incorporated, as this paragraph mainly discusses the relationship between EAT and HF according to imaging modalities, but no mechanistic association is unfolded. 4 Current Interventions Targeting EAT and Future Therapeutic Perspectives in HFpEF with T2DM Line 12 Page 10--- The author stated that “EAT acts as a critical contributor to the development and progression of diabetic HFpEF”. Using “critical” might outweigh the role of EAT too much. Currently, most evidence that EAT leads to HFpEF is based on epidemiology and imaging. Rarely there is any solid histological and pathological evidence confirming the role of EAT in HFpEF. The author needs to tone down the statement. 4.1 Non-pharmacological interventions Line 1 Page 11: “and an improvement in LV hypertrophy ”--- Not an improvement, should be an “alleviation” Line 1 Page 11: “5% reduction ”--- 5% difference in serial imaging assessment can be due to measurement variability. Especially EAT volume is difficult to measure at the apex. Be cautious of the statement or citing this reference. Line 22 Page 12: “EAT regression” means “reverse

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

remodeling"? 4.2.3 Anti-hyperglycemic drugs Line 17 Page 13: "its positive effects on body weight and fat composition" --- It should be "positive effects on reducing body ---" Line 15-17 Page 14: "Therefore, considering the therapeutic effects of modulating PPAR-γ, targeting PPARγ remains a promising treatment approach and deserves the development of new and safer PPARγ-modulating drugs."----- The therapeutic effect of targeting EAT to treat HFpEF might be cancelled out by PPAR-y. The author's saying here needs to be more cautious and conservative. 5 Summary and Future Perspectives Line 7-8 Page 17: "T2DM is an essential driver of the occurrence and development of HFpEF "---This is incorrect. DM can be one of the essential driver, but some HFpEF patients do not have DM.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 82803

Title: Targeting Epicardial Adipose Tissue: A Potential Therapeutic Strategy for Heart Failure with Preserved Ejection Fraction with Type 2 Diabetes Mellitus

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02623966
Position: Editorial Board
Academic degree: MD, MSc, PhD
Professional title: Attending Doctor, Doctor, Research Scientist
Reviewer's Country/Territory: Greece
Author's Country/Territory: China

Manuscript submission date: 2022-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-01-25 11:01

Reviewer performed review: 2023-01-25 11:02

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation
Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [ ] Anonymous [Y] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

It is a well-design study adding new information to the literature. According to my knowledge, it is a novel paper in its field opening new horizons for further evidence. Authors, succeed to present their findings in a clear way. In addition, the object as well as the results are appropriately discussed in the context of previous literature explaining the importance of the manuscript in its field. Authors succeed to present their data in a clear way adding information to the existing literature. Therefore, I have no corrections or further work to propose for the improvement of the manuscript and therefore it can be published unaltered.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 82803

Title: Targeting Epicardial Adipose Tissue: A Potential Therapeutic Strategy for Heart Failure with Preserved Ejection Fraction with Type 2 Diabetes Mellitus

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02601711
Position: Editorial Board
Academic degree: BSc, PhD
Professional title: Senior Researcher
Reviewer's Country/Territory: Spain
Author's Country/Territory: China

Manuscript submission date: 2022-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-01-22 19:56

Reviewer performed review: 2023-02-01 10:50

Review time: 9 Days and 14 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation
Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

There are two important reviews in the same field: 1. van Woerden G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, Rienstra M, Gorter TM. Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives. Eur J Heart Fail. 2022 Dec;24(12):2238-2250. doi: 10.1002/ejhf.2741. 2. Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail. 2020 Sep;22(9):1551-1567. doi: 10.1002/ejhf.1902. However, this manuscript includes type 2 diabetes mellitus on HFpEF and its association with epicardial fat. There is a special interest on this field the last years. The authors have explained in detail all the principal aspects: The physiopathological mechanisms and the non and pharmacologycal therapeutic strategies.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 82803

Title: Targeting Epicardial Adipose Tissue: A Potential Therapeutic Strategy for Heart Failure with Preserved Ejection Fraction with Type 2 Diabetes Mellitus

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06476778
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer's Country/Territory: China
Author's Country/Territory: China

Manuscript submission date: 2022-12-28

Reviewer chosen by: Han Zhang

Reviewer accepted review: 2023-03-21 15:04

Reviewer performed review: 2023-03-22 03:09

Review time: 12 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The revised manuscript has a substantial improvement. I have no other comments.